JP2009510046A5 - - Google Patents

Download PDF

Info

Publication number
JP2009510046A5
JP2009510046A5 JP2008532878A JP2008532878A JP2009510046A5 JP 2009510046 A5 JP2009510046 A5 JP 2009510046A5 JP 2008532878 A JP2008532878 A JP 2008532878A JP 2008532878 A JP2008532878 A JP 2008532878A JP 2009510046 A5 JP2009510046 A5 JP 2009510046A5
Authority
JP
Japan
Prior art keywords
sample
seen
bands
run
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008532878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510046A (ja
Filing date
Publication date
Priority claimed from GBGB0519923.7A external-priority patent/GB0519923D0/en
Application filed filed Critical
Priority claimed from PCT/GB2006/003650 external-priority patent/WO2007036745A2/en
Publication of JP2009510046A publication Critical patent/JP2009510046A/ja
Publication of JP2009510046A5 publication Critical patent/JP2009510046A5/ja
Pending legal-status Critical Current

Links

JP2008532878A 2005-09-30 2006-09-29 インターロイキン−１３抗体組成物 Pending JP2009510046A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72197405P 2005-09-30 2005-09-30
GBGB0519923.7A GB0519923D0 (en) 2005-09-30 2005-09-30 Interleukin-13 antibody composition
PCT/GB2006/003650 WO2007036745A2 (en) 2005-09-30 2006-09-29 Interleukin-13 antibody composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013212846A Division JP5820450B2 (ja) 2005-09-30 2013-10-10 インターロイキン−１３抗体組成物

Publications (2)

Publication Number Publication Date
JP2009510046A JP2009510046A (ja) 2009-03-12
JP2009510046A5 true JP2009510046A5 (enExample) 2009-07-09

Family

ID=37434894

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008532878A Pending JP2009510046A (ja) 2005-09-30 2006-09-29 インターロイキン−１３抗体組成物
JP2013212846A Active JP5820450B2 (ja) 2005-09-30 2013-10-10 インターロイキン−１３抗体組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013212846A Active JP5820450B2 (ja) 2005-09-30 2013-10-10 インターロイキン−１３抗体組成物

Country Status (21)

Country Link
US (3) US20080248048A1 (enExample)
EP (1) EP1942939B2 (enExample)
JP (2) JP2009510046A (enExample)
KR (1) KR101363777B1 (enExample)
AU (1) AU2006296399B2 (enExample)
BE (1) BE2021C552I2 (enExample)
BR (1) BRPI0616359B8 (enExample)
CA (1) CA2623429C (enExample)
CY (2) CY1120874T1 (enExample)
FI (1) FIC20210042I1 (enExample)
FR (1) FR21C1055I2 (enExample)
GB (1) GB2430883B (enExample)
HU (1) HUS2100053I1 (enExample)
IL (3) IL189983A (enExample)
LT (1) LTC1942939I2 (enExample)
LU (1) LUC00239I2 (enExample)
NL (1) NL301143I2 (enExample)
NO (2) NO344859B1 (enExample)
PL (1) PL1942939T5 (enExample)
SI (1) SI1942939T2 (enExample)
WO (1) WO2007036745A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420086B2 (en) * 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
DK2805728T3 (da) 2003-12-23 2020-04-20 Genentech Inc Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
MX2008012896A (es) 2006-04-05 2008-10-14 Abbott Biotech Ltd Purificacion de anticuerpos.
EP2114451A2 (en) * 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Anti-il-13 antibody formulations and uses thereof
WO2009002521A2 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
WO2009009406A1 (en) * 2007-07-06 2009-01-15 Smithkline Beecham Corporation Antibody formulations
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
RU2607569C2 (ru) 2008-03-31 2017-01-10 Дженентек, Инк. Композиции и способы для лечения и диагностики астмы
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
EP3037104B1 (en) 2009-10-20 2020-05-27 AbbVie Inc. Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
JP6005657B2 (ja) 2010-12-16 2016-10-12 ジェネンテック， インコーポレイテッド Ｔｈ２阻害に関連する診断及び治療
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
BR112013025845A2 (pt) * 2011-04-07 2018-09-04 Glaxosmithkline Llc formulações com viscosidade reduzida
AU2012283039A1 (en) * 2011-07-13 2014-01-30 Abbvie Inc. Methods and compositions for treating asthma using anti-IL-13 antibodies
LT3091029T (lt) 2011-10-31 2023-02-27 F. Hoffmann-La Roche Ag Anti-il13 antikūno kompozicijos
CN104334744A (zh) 2012-03-27 2015-02-04 弗·哈夫曼-拉罗切有限公司 预测、诊断和治疗特发性肺纤维化的方法
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
SG10201802525QA (en) 2013-09-13 2018-04-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
KR102332302B1 (ko) 2013-09-13 2021-12-01 제넨테크, 인크. 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
BR112016008694A2 (pt) 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
JP2014062100A (ja) * 2013-11-05 2014-04-10 Glaxosmithkline Llc 抗体処方
CN106029693A (zh) 2014-02-21 2016-10-12 豪夫迈·罗氏有限公司 抗il-13/il-17双特异性抗体及其用途
CN106030304B (zh) * 2014-02-27 2018-02-06 得克萨斯大学体系董事会 用于分离外来体的方法和组合物
WO2015155710A1 (en) 2014-04-11 2015-10-15 Novartis Ag Methods of selectively treating asthma using il-13 antagonists
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP6247241B2 (ja) * 2015-02-27 2017-12-13 ノバルティス アーゲー 抗体処方
CA2977285A1 (en) 2015-03-16 2016-09-22 F. Hoffmann-La Roche Ag Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2017139290A1 (en) * 2016-02-10 2017-08-17 Medimmune, Llc Tralokinumab delivery device
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
CA3031589C (en) 2016-09-23 2025-05-06 Genentech, Inc. USES OF IL-13 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DERMATITIS
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3749362A1 (en) 2018-02-09 2020-12-16 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
JP7467438B2 (ja) 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
CN113015748B (zh) 2018-10-31 2025-12-12 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
WO2021191220A1 (en) 2020-03-23 2021-09-30 Medimmune Limited Methods for treating atopic dermatitis and related disorders
US12187788B2 (en) 2020-03-23 2025-01-07 Medimmune Limited Methods for treating atopic dermatitis and related disorders
GB202108379D0 (en) 2021-06-11 2021-07-28 Medlmmune Ltd Methods for treating a topic dermatitis and related disorders
WO2023023497A1 (en) 2021-08-16 2023-02-23 Medimmune Llc Anti-il-13 antibody formulation
IL311027A (en) 2021-09-15 2024-04-01 Dermira Inc Il-13 inhibitors for the treatment of prurigo nodularis
WO2023052408A1 (en) 2021-09-28 2023-04-06 Medimmune Limited Methods for treating atopic dermatitis and related disorders
WO2025128984A1 (en) 2023-12-14 2025-06-19 Dermira, Inc. Il-13 antibodies for the treatment of chronic rhinosinusitis with nasal polyps
TW202544035A (zh) 2023-12-14 2025-11-16 美商德米拉股份有限公司 用於治療全年性過敏性鼻炎之il-13抗體
WO2025184453A1 (en) 2024-03-01 2025-09-04 Dermira, Inc. Il-13 antibodies for the treatment of post-inflammatory hyperpigmentation or hypopigmentation of skin

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU217099B (hu) * 1991-03-29 1999-11-29 Elf Sanofi Sa. Eljárás citokin típusú aktivitással rendelkező fehérje, azt kódoló rekombináns DNS-szekvencia és a megfelelő transzformált sejtek és mikroorganizmusok előállítására
FR2685919B1 (fr) * 1992-01-08 1994-04-08 Elf Sanofi Proteine a activite de type cytokine, adn recombinant codant pour cette proteine, cellules animales transformees.
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
JPH07267994A (ja) * 1994-03-31 1995-10-17 Snow Brand Milk Prod Co Ltd 新規蛋白質及びその製造法
JP3414856B2 (ja) * 1994-08-09 2003-06-09 株式会社ヤトロン ジフェニルエーテル化合物の免疫学的測定方法
US5866154A (en) † 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
SK150298A3 (en) † 1996-05-04 1999-04-13 Zeneca Ltd Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
ES2229784T3 (es) † 1998-06-09 2005-04-16 Statens Serum Institut Proceso de produccion de inmunoglobulinas para administracion intravenosa y otros productos de inmunoglobulina.
JP3537331B2 (ja) * 1998-11-17 2004-06-14 積水化学工業株式会社 Ｉｖ型コラーゲンの免疫測定法及び試薬
BRPI0108923B8 (pt) † 2000-03-03 2021-05-25 Cambridge Antibody Tech Limited elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
EP1175931A1 (en) † 2000-07-25 2002-01-30 Computer Cell Culture Center S.A. Integration of high cell density bioreactor operation with ultra fast on-line downstream processing
AU2002355285A1 (en) † 2001-07-23 2003-02-17 Accurate Polymers, Inc. High-speed, solid-liquid separation
EP1578912A4 (en) * 2001-10-26 2007-12-26 Centocor Inc IL-13 MUTEIN PROTEINS, ANTIBODIES, COMPOSITIONS, METHODS AND USES
US20040248260A1 (en) 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
US20040234499A1 (en) * 2001-10-26 2004-11-25 David Shealy Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
AU2003223497A1 (en) 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
CA2490423A1 (en) * 2002-06-21 2003-12-31 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
EP1601697B1 (en) † 2003-02-28 2007-05-30 Lonza Biologics plc Antibody purification by Protein A and ion exchange chromatography
EP1614693A4 (en) † 2003-03-31 2006-07-19 Kirin Brewery Purification of a human monoclonal antibody and human polyclonal antibody
HRP20050934B1 (hr) * 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
DK2805728T3 (da) † 2003-12-23 2020-04-20 Genentech Inc Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf
CN1234725C (zh) † 2004-04-07 2006-01-04 陈志南 一种高效快速纯化制备片段抗体的方法
AR049390A1 (es) † 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
EP1793856A2 (en) * 2004-08-20 2007-06-13 Amgen Inc. Methods and compositions for treating allergic inflammation
WO2006055638A2 (en) * 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
US20060171943A1 (en) * 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
BR112013009173A2 (pt) † 2010-10-14 2016-07-26 Ticona Gmbh polioximetileno plastificante

Similar Documents

Publication Publication Date Title
JP2009510046A5 (enExample)
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
BR112021020023A2 (pt) Ligantes de conjugação melhorados
WO2017085172A3 (en) Improved serum albumin binders
CL2013000951A1 (es) Anticuerpo que presenta alta afinidad con proteinas tau solubles e insoluble y modula los niveles tau solubles e insolubles; peptido de union; composicion farmaceutica que comprende el peptido o proteina de union, un anticuerpo o polinucleotido; uso para tratar enfermedad neurodegenerativa.
WO2017197014A3 (en) Compositions comprising a polymeric dye and a cyclodextrin and uses thereof
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
WO2015073884A3 (en) Glycoengineered antibody compositions
EA200801918A1 (ru) Агрохимические препараты
CU20180024A7 (es) Moléculas de unión a linfopoyetina estromal tímica (tslp), composiciones farmacéuticas que las contienen y método de producción de las mismas
WO2014059442A8 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
TR201909218T4 (tr) Pestisit işlevine sahip moleküller ve bunlarla ilişkili aramaddeler, bileşimler ve işlemler.
BR112013030163A2 (pt) composto, uso cosmético de pelo menos um composto, composição farmacêutica ou cosmética e processo para preparar um composto.
NO347649B1 (no) Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
BR112015001841A2 (pt) filete ou listra de segurança, processo para fazer o mesmo ,substrato de segurança, processo para fazer o mesmo , uso do filete ou listra de segurança e documento de segurança.
EA201690731A1 (ru) Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
WO2015075269A9 (en) Antibodies against ccr9 and applications thereof
BR112014025707A2 (pt) produto de condensação com base em monômero, processo para a preparação do mesmo, seu uso e composição compreendendo o mesmo.
EP4443155A3 (en) Encapsulated pre-analytic workflows for flow-through devices, liquid chromatography and mass spectrometric analysis
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
WO2017153329A3 (en) A particulate earth alkali carbonate-comprising material and/or particulate earth alkali phosphate-comprising material for nox uptake
GB201014028D0 (en) In-situ reagent
EA200970597A1 (ru) Новые бис(диалкиламиды), способ получения и применения